Ai Jian, Tang Xin, Mao Bingyong, Zhang Qiuxiang, Zhao Jianxin, Chen Wei, Cui Shumao
State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi, China.
School of Food Science and Technology, Jiangnan University, Wuxi, China.
Crit Rev Food Sci Nutr. 2025;65(18):3546-3568. doi: 10.1080/10408398.2024.2369169. Epub 2024 Jun 28.
Mounting evidence implicates the gut microbiota as a possible key susceptibility factor for atherosclerosis (AS). The employment of dietary phytochemicals that strive to target the gut microbiota has gained scientific support for treating AS. This study conducted a general overview of the links between the gut microbiota and AS, and summarized available evidence that dietary phytochemicals improve AS manipulating gut microbiota. Then, the microbial metabolism of several dietary phytochemicals was summarized, along with a discussion on the metabolites formed and the biotransformation pathways involving key gut bacteria and enzymes. This study additionally focused on the anti-atherosclerotic potential of representative metabolites from dietary phytochemicals, and investigated their underlying molecular mechanisms. In summary, microbiota-dependent dietary phytochemical therapy is a promising strategy for AS management, and knowledge of "phytochemical-microbiota-biotransformation" may be a breakthrough in the search for novel anti-atherogenic agents.
越来越多的证据表明，肠道微生物群可能是动脉粥样硬化（AS）的一个关键易感性因素。使用旨在针对肠道微生物群的膳食植物化学物质在治疗AS方面已获得科学支持。本研究对肠道微生物群与AS之间的联系进行了全面概述，并总结了现有证据，即膳食植物化学物质通过操纵肠道微生物群来改善AS。然后，总结了几种膳食植物化学物质的微生物代谢情况，并讨论了形成的代谢产物以及涉及关键肠道细菌和酶的生物转化途径。本研究还重点关注了膳食植物化学物质代表性代谢产物的抗动脉粥样硬化潜力，并研究了其潜在的分子机制。总之，依赖微生物群的膳食植物化学物质疗法是AS管理的一种有前景的策略，而“植物化学物质-微生物群-生物转化”的知识可能是寻找新型抗动脉粥样硬化药物的一个突破。
